Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 8,300 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabete Mellitus Clear all
Completed Phase 4 Interventional Results available

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery

NCT00596687
View directory record Official record
Conditions
Type 2 Diabetes, Inpatient Hyperglycemia
Interventions
Insulin glargine, Regular insulin, Insulin glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 2, 2026, 12:45 AM EDT
Completed No phase listed Observational

Performance Evaluation of a Non-Invasive Glucose Monitor as Compared to CGM Data Acquired by the iPro2

NCT01831752
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
12 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 1 Interventional

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

NCT00952198
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ARRY-403, glucokinase activator; oral, Placebo; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT02284893
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

NCT00504816
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075, Brevicon
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 2, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Risk Progression in Normal and Diabetic Control Subjects.

NCT00579228
View directory record Official record
Conditions
Diabetes, Inflammation
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 2, 2026, 12:45 AM EDT
Recruiting Phase 2 Interventional

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

NCT05762107
View directory record Official record
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg
Drug
Lead sponsor
Zucara Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Completed No phase listed Observational Results available

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

NCT01400971
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Little Rock, Arkansas • Orlando, Florida • Wellington, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 2, 2026, 12:45 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

NCT05704309
View directory record Official record
Conditions
Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
Interventions
Not listed
Lead sponsor
Marinella Temprosa
Other
Eligibility
Not listed
Enrollment
1,976 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 2, 2026, 12:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Studies of Insulin and Diabetes

NCT00001987
View directory record Official record
Conditions
Diabetes Mellitus, Severe Insulin Resistance
Interventions
HR-pQCT scan
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1976
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Safety and Efficacy of the Noxsano Wound Care Bandage

NCT04123093
View directory record Official record
Conditions
Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot, Diabetic Foot Ulcer, Arterial Insufficiency
Interventions
Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care)
Device
Lead sponsor
OhioHealth
Other
Eligibility
18 Years to 79 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 2, 2026, 12:45 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00318214
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094, Vehicle gel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 2, 2026, 12:45 AM EDT
Enrolling by invitation Not applicable Interventional

Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening

NCT07332416
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 1 Interventional

Type 1 Diabetes Data Acquisition and Transfer Adherence Study

NCT03228004
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glooko MeterSync
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

NCT06599684
View directory record Official record
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

NCT04877730
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Fully Closed Loop (FCL), Fully Closed Loop with meal anticipation module (FCL+), Hybrid Closed Loop (HCL)
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Not applicable Interventional

SDRM® vs. Collagen for Diabetic Foot Ulcers

NCT05883098
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Wound Heal
Interventions
Wound debridement, Wound closure matrix application
Procedure · Device
Lead sponsor
Polymedics Innovations Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

NCT01292798
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

NCT03029702
View directory record Official record
Conditions
Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
Interventions
Insulin, Glyburide, Metformin
Drug
Lead sponsor
Maisa N. Feghali, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 2, 2026, 12:45 AM EDT
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes

NCT01754467
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
NEAT!
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

NCT00705536
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 2, 2026, 12:45 AM EDT
Not listed No phase listed Observational

Continuous Monitoring and Control of Hypoglycemia

NCT03340831
View directory record Official record
Conditions
Diabetes
Interventions
Continuous Glucose Monitoring (CGM)
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
25
States / cities
La Jolla, California • La Mesa, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 4 Interventional

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 2, 2026, 12:45 AM EDT